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DNA methyltransferase 3a (DNMT3A) catalyzes
the formation of 5-methyl-cytosine in mammalian
genomic DNA, and it is frequently mutated in human
hematologic malignancies. Bi-allelic loss of Dnmt3a
in mice results in leukemia and lymphoma, including
chronic lymphocytic leukemia (CLL). Here, we inves-
tigate whether mono-allelic loss of Dnmt3a is suffi-
cient to induce disease. We show that, by 16 months
of age, 65% of Dnmt3a+/ mice develop a CLL-like
disease, and 15% of mice develop non-malignant
myeloproliferation. Genome-wide methylation anal-
ysis reveals that reduced Dnmt3a levels induce pro-
moter hypomethylation at similar loci in Dnmt3a+/
and Dnmt3aD/D CLL, suggesting that promoters are
particularly sensitive to Dnmt3a levels. Gene expres-
sion analysis identified 26 hypomethylated and over-
expressed genes common to both Dnmt3a+/ and
Dnmt3aD/D CLL as putative oncogenic drivers. Our
data provide evidence that Dnmt3a is a haplo-insuf-
ficient tumor suppressor in CLL and highlights the
importance of deregulated molecular events in dis-
ease pathogenesis.
INTRODUCTION
DNA methyltransferase 3a (Dnmt3a) is an enzyme important
for the generation and maintenance of 5-methyl-cytosine in
mammalian genomic DNA. The methylation of gene promoters
is typically associated with gene repression and plays an
important role in the silencing of endogenous retroviral elements,
X chromosome inactivation, imprinting, and differentiation. In
particular, cytosine methylation plays a critical role in hemato-1190 Cell Reports 15, 1190–1201, May 10, 2016 ª 2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://poiesis, and its deregulation contributes to hematologic malig-
nancies (Yang et al., 2015). This is highlighted by the presence
of mutations in the DNMT3A gene in a wide variety of human he-
matologic malignancies of myeloid and T cell origin (Yang et al.,
2015). Although the precise biological and molecular functions
by which DNMT3A prevents cellular transformation are poorly
understood, functional studies in mice have begun to uncover
the role of Dnmt3a in hematopoiesis. Long-term Dnmt3a defi-
ciency inhibits the ability of hematopoietic stem cells (HSCs) to
differentiate into hematopoietic lineages, promoting the devel-
opment of various hematologic malignancies, including myelo-
dysplastic syndrome, acute myeloid leukemia, and acute
lymphoblastic leukemia of T and B cell origin (Challen et al.,
2011, 2014; Mayle et al., 2015). Introduction of genetic alter-
ations found in hematologic malignancies into a Dnmt3a-
deficient background often results in enhanced phenotypes.
For example, Dnmt3a deficiency, in combination with c-Kit over-
expression, induces acute T and B cell leukemia (Celik et al.,
2015) and, when associated with KrasG12D/+, promotes progres-
sion of juvenile and chronic myelomonocytic leukemia (Chang
et al., 2015). Given the multiple genome-wide activities associ-
ated with Dnmt3a, such as de novo methylation (Okano et al.,
1999), maintenancemethylation (Jeong et al., 2014), andmethyl-
ation-independent repression (Datta et al., 2005), it is not sur-
prising that, under some circumstances, Dnmt3a may promote
the development of hematologic malignancies. For example,
upregulation of Dnmt3a promotes AML1/ETO-induced leukemia
through de novo hypermethylation (Gao et al., 2015), and
methylation-independent repressor function enhances T cell
lymphomagenesis (Haney et al., 2015). Such studies highlight
the importance of the context-dependent activities of Dnmt3a
in hematologic malignancies. DNMT3A mutations in human
hematologic malignancies are usually heterozygous and most
commonly occur at amino acid 882. DNMT3A R882H mu-
tants show both decreased methyltransferase activity (Russler-
Germain et al., 2014) and dominant-negative functions ascreativecommons.org/licenses/by-nc-nd/4.0/).
their overexpression results in hypomethylation (Kim et al.,
2013). Therefore, a partial, rather than complete, inactivation of
DNMT3A is likely more relevant in the pathogenesis of human
hematologic malignancies. The effects of decreased levels of
Dnmt3a in the prevention of hematologic malignancies, how-
ever, are poorly understood.
We have previously utilized EmSRa-tTA;Teto-Cre;Dnmt3afl/fl;
Rosa26 LOXP EGFP/EGFP quadruple-transgenic mice (designated
here as Dnmt3aD/D mice) to conditionally inactivate Dnmt3a
in HSCs and hematopoietic lineages (Peters et al., 2014).
Surprisingly, all Dnmt3aD/D mice developed disease similar to
chronic lymphocytic leukemia (CLL), with a median survival of
371 days characterized by an expansion of EGFP-positive
(EGFP+) mature B220+CD19+CD5+ B cells (B-1a cells) in
hematopoietic organs. Here, we examined whether Dnmt3a
haploinsufficiency can result in the development of a CLL-like
disease or other hematologic malignancies by observing
Dnmt3a+/ mice. We show that, whereas a decrease in Dnmt3a
levels is insufficient to immediately induce cellular trans-
formation of hematopoietic cells, long-term Dnmt3a decrease
results in the development of a CLL-like disease in 65% of
mice and myeloproliferative disease in 15% of mice within
16 months. Whole-genome bisulfite sequencing (WGBS) and
RNA sequencing (RNA-seq) revealed that a significant cohort
of methylation and expression changes was conserved in
Dnmt3a+/ and Dnmt3aD/D CLL. Ingenuity pathway analysis
(IPA) analysis revealed a signature of putative oncogenes
that may drive CLL development. Altogether, our data demon-
strate that a small reduction of Dnmt3a levels has profound
phenotypic consequence on both cellular and molecular levels,
identifying Dnmt3a as a critical gene preventing B-1a cell
transformation.
RESULTS
The Majority of Dnmt3a+/ Mice Develop a CLL-like
Disease
During the course of our studies utilizingDnmt3aD/Dmice (Peters
et al., 2014), we also observed an EmSRa-tTA;Teto-Cre;
Dnmt3+/fl;Rosa26LOXPEGFP/EGFP mouse in which only one allele
of Dnmt3a was conditionally inactivated (referred to hereinafter
as Dnmt3a+/D or conditional heterozygous mouse). This mouse
became moribund at 16 months, and analysis of the organs
revealed expansion of EGFP+ B220+CD19+CD5+ (B-1a) cells
in the spleen, suggesting that this mouse developed a CLL-like
disease (Figure 1A). Serial transplantation of Dnmt3a+/D splenic
cells induced CLL within 4 months in primary, secondary, and
tertiary transplanted mice, illustrating their selective advantage
to grow and induce disease (Figures S1A and S1B). Dnmt3a+/D
CLL cells showed reduced Dnmt3a protein and mRNA levels
(Figures 1B and 1C), suggesting that decreased Dnmt3a dosage
is sufficient to promote B-1a cell transformation. Dnmt3a+/D tu-
mor cells incorporated bromodeoxyuridine (BrdU) in vivo less
efficiently than Dnmt3aD/D cells (Figure S1C). These data sug-
gest that Dnmt3a haploinsufficiency in hematopoietic cells, like
full Dnmt3a inactivation, might be sufficient to induce a less
aggressive CLL-like disease in mice. To test this, we generated
Dnmt3a+/ mice harboring a conventional Dnmt3a knockoutallele (referred to hereinafter asDnmt3a) via germline Cre-medi-
ated excision of Dnmt3a exons 18–20 (Figure S2A) (Dnmt3afl;
Nguyen et al., 2007). Generation of the Dnmt3a allele was
confirmed by PCR-based genotyping (Figure S2B). Analysis of
protein levels in normal thymus and spleen isolated from
6-week-oldDnmt3a+/mice showed50% reduction in Dnmt3a
protein levels (Figure 1D). This decrease had no measurable
effect on hematopoiesis in 6-week-old Dnmt3a+/mice (Figures
S2C–S2G).
At 16 months of age, all Dnmt3a+/+ control mice were healthy,
with no signs of deregulated hematopoiesis. In contrast, only
20% of Dnmt3a+/ mice were disease-free at 16 months (Fig-
ure 1E; data not shown). Five out of 20 Dnmt3a+/ mice devel-
oped a CLL-like disease, characterized by B-1a cell expansion
greater than 20% in the blood, spleen, and bonemarrow (Figures
1E–1I; data not shown). Eight Dnmt3a+/ mice showed signs of
monoclonal B cell lymphocytosis (MBL)—a less progressed
form of CLL—in which the percentage of B-1a cells in the blood
are between 2% and 20%, with simultaneous expansion in the
spleen and bonemarrow (Figures 1E–1I; data not shown). Impor-
tantly, splenic cells either from mice with MBL or CLL were able
to induce disease in recipient mice (Figures 1I and 1J), demon-
strating that both populations contain true leukemic cells. There-
fore, we refer to both conditions as CLL-like disease. Similar to
Dnmt3a+/D CLL, leukemic B-1a cells isolated from Dnmt3a+/
mice retained 50% expression of Dnmt3a, suggesting that
the remaining allele is expressed in fully transformed cells (Fig-
ures 1K and 1L). Importantly, sequencing analysis of tumor
cDNA generated from three independent Dnmt3a+/ mice with
CLL revealed no mutations in the coding sequence of Dnmt3a
(data not shown), demonstrating that the expressed Dnmt3a
allele is in the wild-type configuration. Altogether, these data
suggest that Dnmt3a is a haploinsufficient tumor suppressor
gene in the prevention of CLL in mice.
Dnmt3a+/ Mice Also Develop Myeloproliferative
Disease
In addition to CLL, we also observed the development of a
myeloproliferative disease (MPD) in 15%ofDnmt3a+/mice (Fig-
ure 1E). These mice showed expansion of Gr-1+CD11b+
myeloid cells in the blood, spleen, and bone marrow (Fig-
ures 2A–2C; data not shown). In contrast to CLL-like cells,
Gr-1+CD11b+ splenic cells did not induce disease upon injec-
tion into sublethally irradiated FVB recipient mice, suggesting
that this population of cells does not contain leukemia-initiating
cells (Figures 2D and 2E). Thus, our studies of Dnmt3a+/ mice
show that long-term mono-allelic loss of Dnmt3a can induce a
frank B cell malignancy, non-malignant myeloproliferative disor-
der with a combined 80% penetrance by 16 months of age. In
order to understand why Dnmt3a heterozygosity affects pri-
marily B-1a and myeloid cells, we measured Dnmt3a mRNA
levels in normal Dnmt3a+/+ B-1a, B2, and T cells and myeloid
cells that were sorted by FACS (fluorescence-activated cell sort-
ing) and found that Dnmt3a expression was lower in B-1a cells
when compared to B2 cells and relatively equal when compared
to T cells (Figure 2F). Thus, the preferential transformation of
B-1a cells or myeloid cells does not seem to be associated
with significantly different Dnmt3a levels relative to other normalCell Reports 15, 1190–1201, May 10, 2016 1191
Figure 1. Dnmt3a-Heterozygous Mice
Develop CLL
(A) Flow diagram of CD5 and CD19 expression is
shown for EGFP-negative (black) and EGFP+
(green) cells from a Dnmt3a+/D spleen. The per-
centage of positive cells is indicated in quadrants.
(B) Dnmt3a expression in Dnmt3a+/D spleen as
determined by immunoblot using anti-Dnmt3a
antibody. N indicates Dnmt3a+/+ CD19+ splenic
cells. +/D and D/D indicate splenic CLL cells from
Dnmt3a+/D and Dnmt3aD/D mice, respectively. 3a
represents a positive control in which Dnmt3a
protein was overexpressed in Dnmt3a/ cells.
g-tubulin served as a loading control.
(C) qRT-PCR analysis of Dnmt3a expression in
normal splenic B-1a (B1) cells andDnmt3a+/D (+/D)
CLL. Average of two independent experiments is
presented. Error bars represent ±SD. p < 0.05,
Student’s t test. Statistically significant difference
is indicated by an asterisk.
(D) Dnmt3a expression in thymi (Th) and spleens of
6-week-old Dnmt3a+/+ (+/+) and Dnmt3a+/ (+/)
mice as determined by immunoblot using anti-
Dnmt3a antibody. (/) represents Dnmt3a-defi-
cient cells. g-tubulin served as a loading control.
(E) Disease spectrum observed in 16-month-old
Dnmt3a+/ mice (n = 20). no disease, disease-free
mice.
(F) Flow diagram of CD5 and CD19 expression in
spleens of Dnmt3a+/ (+/) and age-matched
Dnmt3a+/+ (+/+) mice.
(G) H&E-stained sections of Dnmt3a+/+ (normal)
and Dnmt3a+/ (CLL) spleens (2003).
(H)PercentageofB-1acells in thespleensandblood
of 16-month-old Dnmt3a+/+ (blue) and Dnmt3a+/
(red) mice as determined by FACS. Number of mice
(n) is shown. *p < 0.05, Student’s t test.
(I) Flow diagram of CD5 and CD19 expression in
the spleen of a Dnmt3a+/ mouse with MBL (top)
and terminally ill FVB recipient mouse injected (Inj.)
with MBL splenic cells.
(J) Kaplan-Meier survival curves for FVB mice
injected with Dnmt3a+/ MBL/CLL splenic cells
(three mice per line). Five primary MBL/CLL mice
are shown.
(K) Dnmt3a expression in spleens of Dnmt3a+/ (+/) and Dnmt3aD/D (D/D) mice as determined by immunoblot using anti-Dnmt3a antibody. N indicates
Dnmt3a+/+ CD19+ splenic cells. g-tubulin served as a loading control.
(L) qRT-PCR analysis of Dnmt3a expression in normal and leukemic Dnmt3a+/ B-1a cells. Average of two independent experiments is shown. Error bars
represent ±SD.hematopoietic cells. Therefore, the reason why B-1a and, to
some extent, myeloid cells are, in particular, sensitive to transfor-
mation upon decreased Dnmt3a levels remains unclear.
Given that Dnmt3a+/ mice develop CLL, we next asked
whether DNMT3A deficiency is observed in human CLL. Previ-
ous analysis of available gene expression data (Haferlach
et al., 2010) identified DNMT3A as belonging to the top 1%of un-
der-expressed genes in CLL (Peters et al., 2014). Our further
analysis showed that in four out of five cases of primary human
CLL, DNMT3A expression was significantly decreased relative
to normal human CD19+ B cells (Figure 2G). These data support
the idea that decreasedDNMT3Amay promote the development
of human CLL. Further investigation is needed to more carefully
address this point.1192 Cell Reports 15, 1190–1201, May 10, 2016DNAMethylome and Transcriptome of Normal Mouse B-
1a Cells
To identify DNA methylation and transcriptional changes associ-
ated with CLL development, we performed global methylation
profiling by WGBS and gene expression profiling by RNA-seq of
B-1a cells isolated fromnormalDnmt3a+/+ spleens, as this cellular
population is immunophenotypically the closest normal counter-
part of CLL cells. We focused on splenic B-1a cells rather than
B-1a cells residing in the intraperitoneal cavity because: (1) the
observed CLL consistently presented with splenomegaly, and
the spleen served as a source of tumor cells; and (2) the microen-
vironment can effect gene expression and, presumably, methyl-
ation patterns. WGBS analysis of normal B-1a cells revealed
that,outof22,452,960CpGdinucleotidescoveredbyouranalysis,
Figure 2. Dnmt3a+/ Mice Also Develop Non-malignant Myeloproliferative Disease
(A) Flow diagram of CD11b and Gr-1 expression in spleens of normal Dnmt3a+/+ (+/+) and Dnmt3a+/ (+/) mice with MPD.
(B) H&E-stained sections of Dnmt3a+/+ and Dnmt3a+/ spleens (2003).
(C) H&E-stained sections of Dnmt3a+/+ and Dnmt3a+/ femurs (2003).
(D) Flow diagram of Gr-1 and CD11b expression in spleen of a Dnmt3a+/mouse with MPD (left). Gr-1 and CD11b expression 9 months post-injection (post inj;
right).
(E) Kaplan-Meier survival curves for FVB recipients injected with two independent Dnmt3a+/ MPD lines (three mice per line).
(F) qRT-PCR analysis of Dnmt3a expression in sorted B-1a cells, B2 cells, CD4+ T cells, CD8+ T cells, and myeloid cells isolated from FVB spleen. Two biological
replicates are shown. Data were normalized to Gapdh, and error bars represent ±SD.
(G) qRT-PCR analysis of DNMT3A expression in five human CLL samples (1–5). Two biological replicates for CD19+ peripheral blood from healthy donors were
used as controls. Average of two independent experiments is shown. Error bars represent ±SD.
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Figure 3. DNA Methylome and Transcriptome of Normal Mouse B-1a Cells
(A) Methylation status of 22,452,960 CpG dinucleotides in normal B-1a cells as determined by WGBS.
(B) A heatmap displaying methylation status of 25,742 promoters as determined by WGBS. Methylation percentages for individual CpGs were annotated to the
promoter regions 300 bp to +150 bp relative to the TSS. Methylation percentages for all CpGs across the 450-bp region were averaged to give a mean
methylation value for each gene promoter.
(C) Heatmap presentation of promoter methylation (analyzed as in Figure 2B) and corresponding gene expression (average FPKMvalues fromRNA-seq) inmouse
splenic B-1a cells for 16,770 genes. Genes with high FPKM values are shown in red, and genes with low FPKM values are shown in green. Upper limit for color
coding in gene expression heatmap is FPKM R 5, as indicated. Heatmaps are organized in the same gene order to match data for methylation and gene
expression.
(D) Analysis of promoter (300 to +150 bp) methylation in relation to gene expression in mouse splenic B-1a cells for 16,770 genes. Genes were divided into four
groups based on percentage of promoter methylation (0%–25%, 26%–50%, 51%–75%, and 76%–100%). p < 0.05 for all pair-wise comparisons except the
51%–75% and 76%–100% groups (Bonferroni’s multiple comparison test).
(E) IPA of 3,700 highly expressed genes (FPKMR 10). The top subcategories obtained in ‘‘Physiological System, Development and Function’’ are shown with the
number of genes indicated above individual bars (p < 0.05, for all subcategories).20,316,133 CpGs were methylated >50%, whereas only
2,136,827 CpGs were methylated <50%, and only 133,765
CpGs were methylated %20% (Figure 3A). When we analyzed
only CpG dinculeotides that aligned to core promoter regions
(300 to+150bp relative to transcription start site; TSS), we found
that, from the 25,742 promoters analyzed, 15,203 were methyl-
ated at >50% (Figure 3B; Table S1), and only 7,436 promoters
were methylated at%20%. A combined analysis of gene expres-1194 Cell Reports 15, 1190–1201, May 10, 2016sion andmethylation revealed that 50%of geneswith%20%pro-
motermethylationwereexpressed (FPKM[fragmentsper kilobase
of exonpermillion fragmentsmapped] >5; Figure3C;TableS2). In
contrast, 84% of genes with promoter hypermethylation (R50%)
were not expressed (FPKM % 5; Figure 3C; Table S2). Consis-
tently, the degree of promoter methylation inversely correlated
with gene expression (Figure 3D). For example, promoters with
<25% methylation were expressed at significantly higher levels
Figure 4. DNA Methylome of CLL Induced
by Decrease or Absence of Dnmt3a
(A) A graphical presentation of differentially
methylated cytosines (DMCS) in Dnmt3a+/D and
Dnmt3aD/D CLL relative to B-1a control. Methyl-
ation changes were evaluated in 15,533,510 CpGs
and are shown in both absolute numbers and
percentages. Hypo, hypomethylated; Hyper, hy-
permethylated.
(B) The number of DMRs associated with gene
bodies in Dnmt3a+/D and Dnmt3aD/D CLL samples
when compared to B-1a control sample.
(C) The number of DMRs associated with long
promoters (1,500 to +500 bp relative to the TSS)
and core promoters (TSS; 300 to +150 bp rela-
tive to the TSS) in Dnmt3a+/D and Dnmt3aD/D CLL
relative to B-1a control.
(D) Circos plot of DMRs associated with long
promoters in Dnmt3a+/D or Dnmt3aD/D CLL. Outer
circle is a graphical presentation of mouse chro-
mosomes, and inner circles indicate DMRs and
their positions on mouse chromosomes observed
inDnmt3a+/D (+/D) orDnmt3aD/DCLL (D/D) relative
to B-1a control. Yellow lines indicate hypomethy-
lated promoters, whereas blue lines indicate hy-
permethylated promoters. Circle C represents
hypo- (red lines) and hypermethylated (green lines)
promoters commonly observed in both CLL sam-
ples.
(E) COBRA assay of putative Dnmt3a target gene
promoters in splenic B-1a cells (B1), Dnmt3a+/D
CLL (+/D), Dnmt3a+/ CLL (+/) and Dnmt3aD/D
CLL (D/D) samples. Undigested (U) and digested
(D) fragments correspond to unmethylated and
methylated DNA, respectively. CpG and M in-
dicates a fully methylated control and undigested
PCR fragments, respectively.
(F) Left: heatmap showing 249 hypomethylated
and 104 hypermethylated promoters identified
through WGBS and confirmed by RRBS. Data are
shown as average percent methylation for
Dnmt3a+/+ B-1a (n = 2) and Dnmt3aD/D CLL (n = 2)
for differentially methylated CpGs (minimum 30%
change in methylation) annotated to the promoter
region (1,500 to +500 bp). Right: heatmap
showing 336 hypomethylated and 34 hyper-
methylated promoters identified through WGBS
and confirmed by MSCC. Data are shown as a fold change in methylation for Dnmt3aD/D CLL (n = 3) relative to Dnmt3a+/+ B-1a (n = 2). Differentially methylated
CpGs (fold change > 2 and p < 0.05, negative binomial analysis) were annotated to the promoter region.
(G) RRBS and MSCC confirmation of differentially methylated promoters (red) identified through WGBS. The number and percentage of confirmed hypo-
methylated (top) and hypermethylated (bottom) genes by RRBS (yellow), MSCC (blue), or both (green) are shown. Gray represents genes identified through
WGBS not confirmed by MSCC or RRBS.thanpromoterswithhigher levels ofmethylation (Figure 3D). IPAof
3,700 highly expressed genes (FPKMR 10) revealed a significant
enrichment in genes relating to hematopoiesis and lymphoid tis-
sue structure and development (Figure 3E). Altogether, these
data demonstrate that most gene promoters in normal splenic
B-1a cells are hypermethylated and silenced, whereas promoters
that are hypomethylated are largely expressed, and their physio-
logical relevance is linked to the hematopoietic system.
DNA Methylome of Dnmt3a+/D and Dnmt3aD/D CLL
Next, we performed WGBS on DNA isolated from Dnmt3a+/D
CLL cells and Dnmt3aD/D CLL cells to determine the effects ofloss of Dnmt3a on the CLL methylome. Mono-allelic loss of
Dnmt3a resulted in an 1% relative hypomethylation and a
0.1% hypermethylation in individual CpGs relative to B-1a (Fig-
ure 4A; Table S3). Bi-allelic loss of Dnmt3a resulted in a substan-
tial 4.1% relative hypomethylation and a 0.1% hypermethylation
in individual CpGs relative to B-1a (Figure 4A; Table S3). Relative
toDnmt3a+/DCLL, hypomethylation in the Dnmt3a-deficient CLL
genome was most pronounced in repetitive elements and gene
bodies (3.5- to 5.5-fold) (Figures 4B, S3A, and S3B). In contrast,
the increased incidence of hypomethylated long promoters
(1,500 bp to +500 bp relative to TSS) was only 2.2-fold greater
in Dnmt3aD/D CLL compared to Dnmt3a+/D CLL (Figures 4C andCell Reports 15, 1190–1201, May 10, 2016 1195
S3B; Table S4). This ratio was even smaller (1.9-fold) when anal-
ysis was restricted to core promoters (300 bp to +150 bp) (Fig-
ures 4C and S3B; Table S4). These data suggest that Dnmt3a
levels are more critical for promoter methylation than other parts
of the genome, such as repetitive elements or gene bodies,
and that 699 hypomethylated promoters in Dnmt3a+/D are likely
hypersensitive to levels of Dnmt3a (Figure 4C). Overall, 386
hypomethylated promoters and 43 hypermethylated promoters
were shared between Dnmt3a+/D and Dnmt3aD/D CLL cells
(Figure 4D; Table S4). Differentially methylated promoters were
equally distributed across the genome, with exception of the
X chromosome, in which no hypo- or hypermethylated pro-
moters were shared between Dnmt3a+/D and Dnmt3aD/D CLL
cells relative to B-1a control cells (Figure 4D; Table S5). In
contrast, chromosome 11 and 19 had the highest number of
commonly hypomethylated promoters, with 48 and 23, respec-
tively (Figure 4D; Table S5). Commonly hypomethylated pro-
moters represent putative targets of Dnmt3a maintenance
methylation function, whereas hypermethylated promoters in
Dnmt3aD/D CLL are likely de novo methylated by other Dnmts.
To determine whether the methylation landscape generated
by WGBS is specific to the CLL samples profiled or, rather,
represents common changes that occur in Dnmt3a-deficient
CLL, we validated hypo- and hypermethylated promoters
using locus-specific combined bisulfite restriction analysis
(COBRA) assays, as well as two global methods: methyl sensi-
tive cut counting (MSCC) and reduced representation bisul-
fite sequencing (RRBS). COBRA assay of six promoters
confirmed the hypomethylation identified by WGBS, suggesting
that changes in promoter methylation likely represent common
events occurring in mouse CLL (Figure 4G; Figure S3C). Next,
we validated hypo- and hypermethylated promoters using two
global methods: MSCC and RRBS. The choice of two indepen-
dent approaches was driven by the fact that each method has
lower genome-wide coverage and is biased against regions
with low-CG content (Hirst and Marra, 2010).Thus, their concur-
rent use allowed us to obtain a more comprehensive and com-
plementary methylation dataset. Importantly, we confirmed
53% of hypomethylated and 98% of hypermethyated differen-
tially methylated regions (DMRs) in promoters in Dnmt3aD/D
CLL identified by WGBS using one or both methods (Figure 4G;
Table S6). These data demonstrate thatmethylation changes de-
tected by WGBS on a small sample set likely represent events
shared among larger sets of Dnmt3aD/D CLL.
Promoter Hypomethylation in CLL Is Likely Due to the
Lack of Cancer-Specific Maintenance Activity of
Dnmt3a and Is Independent of Proliferation
Promoter hypomethylation observed in Dnmt3a+/ and
Dnmt3aD/D CLL could result from Dnmt3a inactivation in normal
B-1a cells, due to lack of Dnmt3a’s de novo or maintenance ac-
tivity. In such a scenario, promoters would be hypomethylated in
normal B-1a cells prior to CLL development. To address this, we
performedCOBRA assays to analyze promotermethylation of 14
genes in normal Dnmt3a+/+ and Dnmt3a+/ B-1a cells. Interest-
ingly, we have not seen any evidence of decreased promoter
methylation in any of the loci tested inDnmt3a+/B-1a cells, sug-
gesting that a partial inactivation of Dnmt3a does not affect the1196 Cell Reports 15, 1190–1201, May 10, 2016methylation status of promoters during the development of
normal B-1a cells (Figure 5A). Thus, the decrease in methylation
observed inDnmt3a+/ and Dnmt3aD/DCLL appears to be tumor
specific.
Next, we sought to determinewhether promoter hypomethyla-
tion observed in Dnmt3a+/ and Dnmt3aD/D CLL could be the
result of increased proliferation of CLL cells rather than the result
of Dnmt3a deficiency. Therefore, we examined promoter methyl-
ation in selected loci in two independent mouse models of CLL,
IRF4/;Vh11, and Em-TCL1 (Shukla et al., 2013; Nganga et al.,
2013). In IRF4/;Vh11 CLL samples, no changes in Dnmt3a
levels were observed through global gene expression (data not
shown). To verify this, we measured the transcript levels of
Dnmt3a but did not observe changes in Dnmt3a transcript levels
in IRF4/;Vh11CLL (Figure 5B). Thus, this CLLmodel likely rep-
resents one in which Dnmt3a activity is not altered. In contrast, it
has been reported recently, that TCL-1 binds to and inhibits
Dnmt3a activity, resulting in suppression of Dnmt3a activity
and hypomethylation in the Em-TCL1 mice (Palamarchuk et al.,
2012). Thus, Em-TCL1 CLL represents a model in which
biochemical inhibition of Dnmt3a occurs. We analyzed promoter
methylation of four genes found to be hypomethylated in
Dnmt3a+/D and Dnmt3aD/D CLL using DNA from IRF4/;Vh11
and Em-TCL1 CLL samples. This analysis revealed that all tested
promoters were partially hypomethylated in Em-TCL1 CLL and
not hypomethylated in IRF4/;Vh11 CLL samples (Figure 5C),
suggesting that promoter hypomethylation in Dnmt3a+/ and
Dnmt3aD/D CLL is directly linked to the lack of Dnmt3a rather
than to increased cellular proliferation. Expression of Nfam1
correlated with its promoter methylation, as this gene was ex-
pressed in Dnmt3a+/ and Dnmt3aD/D CLL but not in IRF4/;
Vh11 CLL, suggesting that at least some genes that become hy-
pomethylated during CLL development become overexpressed
(Figure 5D). These data suggest that Dnmt3a may have a tumor-
specific maintenance activity similar to the one we described
previously for Dnmt3b in MYC-induced T cell lymphomagenesis
(Hlady et al., 2012).
Gene Expression Is Conserved in Dnmt3a+/D and
Dnmt3aD/D CLL
To better understand the molecular basis for CLL development,
global gene expression profiles of normal B-1a cells, as well
as Dnmt3a+/ and Dnmt3aD/D CLL cells, were determined by
RNA-seq. We identified 413 overexpressed and 282 underex-
pressed genes inDnmt3a+/CLL relative toB-1a cells (Figure 6A;
Table S7). Inactivation of both Dnmt3a alleles in Dnmt3aD/D CLL
resulted in overexpression of 790 genes and underexpression of
398 genes. Interestingly, the majority of genes upregulated in
Dnmt3a+/ CLL were also upregulated in Dnmt3aD/D CLL cells
(67%), whereas downregulated genes were less conserved
between the two genetic settings (57%; Figure 6B; Table S7).
To gain insight into the nature of deregulated processes in CLL
induced by decreased levels of Dnmt3a, we next performed
IPA of differentially expressed genes between Dnmt3a+/ and
Dnmt3aD/D CLL relative to control B-1a cells. Notably, the top
five subcategories under ‘‘Top Diseases & Disorders’’ and
‘‘Top Physiological Functions’’ were identical in Dnmt3a+/
and Dnmt3aD/D CLL (Figure S4A). In addition, three out of five
Figure 5. Dnmt3a Has a Cancer-Specific
Maintenance Function
(A) COBRA assay of 14 putative Dnmt3a target
gene promoters in splenic Dnmt3a+/+ and
Dnmt3a+/D B-1a cells. Undigested (U) and di-
gested (D) fragments correspond to unmethylated
and methylated DNA, respectively. CpG and M
indicate a fully methylated control and undigested
PCR fragments, respectively.
(B) qRT-PCR analysis of Dnmt3a expression in
normal B-1a and IRF4/;Vh11 CLL samples.
Average of two independent experiments is
presented. Error bars represent ±SD.
(C) COBRA assay of four putative Dnmt3a target
gene promoters in Dnmt3a+/D (+/D), Dnmt3aD/D
(D/D), Em-TCL1, and IRF4/;Vh11 CLL.
(D) qRT-PCR analysis of Nfam1 expression in
B-1a, IRF4/;Vh11, Dnmt3a+/ (+/), and
Dnmt3aD/D (D/D) CLL. Average of two indepen-
dent experiments is presented. Error bars repre-
sent ±SD. *p < 0.05.subcategories under ‘‘Top Canonical Pathways’’ were
conserved between Dnmt3a+/ and Dnmt3aD/D CLL. Altogether,
this suggests that, despite the higher number of differentially ex-
pressed genes present in Dnmt3aD/D CLL, similar pathways are
affected in both settings. However, the physiological relevance
of these categories to CLL development is less clear, as this
analysis did not provide clear links to pathways or molecules
driving CLL development.
Genes Commonly Hypomethylated and Overexpressed
in Dnmt3a+/ and Dnmt3aD/D CLL Are Putative Drivers
of CLL
Since the loss of one allele of Dnmt3a is sufficient to induce CLL,
we hypothesized that genes most likely involved in the patho-
genesis of the disease are those whose promoter methylation
affects gene expression in both Dnmt3a+/ and Dnmt3aD/D
CLL. A comparison of promoter methylation and gene expres-
sion revealed that 10% of genes in both Dnmt3a+/ and
Dnmt3aD/D CLL were hypomethylated and overexpressed (Fig-
ure 7A; Table S8). In contrast, only 3% and 1% of hypermethy-
lated genes showed reduced expression in Dnmt3a+/ andCell RDnmt3aD/D CLL, respectively (Figure 7A).
Next, we performed IPA using genes
whose expression and methylation was
commonly changed in both Dnmt3a+/
and Dnmt3aD/D CLL. This analysis identi-
fied a signature of 26 genes commonly
hypomethylated and overexpressed in
both Dnmt3a+/ and Dnmt3aD/D CLL
(HOC [hypomethylated and overex-
pressed in CLL] genes; Figure 7B). With
the exception of Mgmt, promoter hypo-
methylation of all HOC genes was
confirmed by locus-specific COBRA
assay in the vast majority of Dnmt3a+/
CLL and Dnmt3aD/D CLL samples tested,
suggesting that HOC promoter hypome-thylation is a conserved event in CLL, induced by a decrease
in Dnmt3a. These genes, therefore, may play a role in disease
development. Consistently, IPA placed 24 genes in the category
‘‘Cancer’’ (Figure S4B). In contrast to the strong association of
HOC genes with the cancer category, IPA of multiple randomly
selected groups of 26 overexpressed genes in Dnmt3a+/ CLL
did not identify the category of ‘‘Cancer’’ as the top category
and failed to yield a single gene associated with cancer (data
not shown), further supporting the idea that HOC genesmay pro-
mote the development of CLL. Thus, combined methylation and
gene expression analysis identified genes likely regulated by
Dnmt3a maintenancemethylation activity that have strong asso-
ciation to cancer and may contain oncogenic drivers of CLL.
DISCUSSION
Identification of Dnmt3a’s molecular targets and understanding
how they regulate cellular functions will enrich our understanding
of the pathogenesis of human blood cancers, given the broad
scope of hematologic malignancies in which the function of
Dnmt3a is altered. Mouse models represent an invaluable tooleports 15, 1190–1201, May 10, 2016 1197
Figure 6. Decreased Dnmt3a Levels Result
in Deregulated Transcription in Dnmt3a+/D
CLL Similar to Dnmt3aD/D CLL
(A) Heatmaps derived from RNA-seq analysis
displaying 413 overexpressed and 282 underex-
pressed genes in Dnmt3a+/D and Dnmt3a+/ CLL
(n = 4) relative to control B-1a cells (n = 2) (left) and
790 overexpressed and 398 underexpressed
genes in Dnmt3aD/D CLL (n = 8). Only genes with a
fold change R 2 and a q value < 0.05 are shown
(CuffDiff analysis).
(B) The number of genes differentially expressed in
Dnmt3aD/D CLL (white boxes), Dnmt3a+/ CLL
(black boxes), and genes common between
Dnmt3aD/D and Dnmt3a+/ CLL (gray boxes).in such efforts, as they allow us to evaluate the phenotypic
and molecular consequences of changes in levels of Dnmt3a
in normal and malignant hematopoiesis. Through functional
studies in mice, we have previously expanded the known dis-
ease spectrum in which Dnmt3a plays a role, as we showed
that complete inactivation of Dnmt3a in cells of the hematopoi-
etic system resulted in the development of a CLL-like disease:
a malignancy of B cell origin that in humans is not known to har-
bor genetic alterations of DNMT3A locus. Rather, decreased
levels of DNMT3A are a common feature of CLL (Haferlach
et al., 2010; Peters et al., 2014), and widespread promoter and
gene-body hypomethylation is characteristic of the CLL methyl-
ome in humans (Kulis et al., 2012). Similarly, in Em-TCL1 mice,
Dnmt3a levels are both decreased and inhibited in early stages
of CLL development, suggesting a role for Dnmt3a in tumor initi-
ation (Chen et al., 2009; Palamarchuk et al., 2012).
In this study, we asked whether a more physiologically rele-
vant setting—a decrease in Dnmt3a, rather than complete
deficiency—can drive the development of hematologic malig-
nancies. By analysis of Dnmt3a+/ mice, we identified Dnmt3a
as a haploinsufficient tumor suppressor gene in the prevention
of CLL and MPD. The overall penetrance of disease in Dnmt3a
heterozygotes (80%) might be even greater, as the 16-month-
old healthy Dnmt3a+/ mice could have developed disease at
a later time. We further demonstrate that Dnmt3a+/ CLL cells
are fully transformed and capable of inducing disease in
wild-type recipient mice, whereas MPD cells fail to engraft in
recipients and appear to represent an expanded population of
non-tumorigenic cells.
To gain insight into the pathogenesis of CLL in mice with
decreased or completely absent Dnmt3a protein, we analyzed
high-resolution methylomes and transcriptomes of normal
splenic B-1a cells, Dnmt3a+/D (or Dnmt3a+/), and Dnmt3aD/D
CLL cells. These analyses resulted in several interesting obser-
vations. First, the methylome of normal B-1a cells consisted
largely of hypermethylated promoters, most of which were asso-
ciated with transcriptional repression. This observation could
explain why only B-1a cells become fully transformed in
Dnmt3aD/D or Dnmt3a+/ mice, despite the decrease in Dnmt3a
levels in all hematopoietic cells. Unlike other terminally differen-
tiated hematopoietic cells, B-1a cells are believed to maintain1198 Cell Reports 15, 1190–1201, May 10, 2016their population through self-renewal. These added cell divi-
sions, along with Dnmt3a deficiency, may further increase the
chances for the accumulation of epimutations over time. This
idea is supported by the recently identified maintenance methyl-
ation activity for Dnmt3a (Jeong et al., 2014), and findings that all
active DNA methyltransferases seem to have cancer-specific
maintenance functions (Hlady et al., 2012; Peters et al., 2013).
Further studies focusing on molecular changes in other B cell
subtypes need to be performed to clarify this point.
Second, we observed that promoter methylation appears to
bemore dependent on high Dnmt3a expression levels than other
parts of the genome. Loss of one allele of Dnmt3a induced hypo-
methylation of 699 2-kb-long promoters (1,500 bp to +500 bp
relative to the TSS) in Dnmt3a+/D CLL. The number of hypome-
thylated promoters was increased only 2.2-fold in Dnmt3aD/D
CLL relative to Dnmt3a+/D CLL. In contrast, hypomethylation of
CpGs distributed across the genome, gene bodies, and repeti-
tive elements was much more pronounced in Dnmt3aD/D CLL
(3.5- to 5-fold) relative to Dnmt3a+/D CLL. Such data suggest
that a select number of promoters are particularly sensitive to
Dnmt3a levels and that the complete absence of Dnmt3a is not
necessary for hypomethylation to occur at these loci.
Last, the number of hypomethylated promoters was 4.9- and
13.2-fold greater than the number of hypermethylated promoters
seen in Dnmt3a+/D and Dnmt3aD/D CLL, respectively. Promoter
hypermethylation was somewhat suppressed in Dnmt3aD/D
CLL, suggesting that Dnmt3a might have tumor-specific de
novo activity. Interestingly, although 3% of hypermethylated
promoters were associated with gene downregulation, these
events were not shared in Dnmt3a+/D and Dnmt3aD/D CLL, sug-
gesting that promoter hypermethylation either contributes to
their pathogenesis differently or does not play a significant
role. Unlike hypermethylation, promoter hypomethylation was
highly conserved between methylomes of Dnmt3a+/D CLL and
Dnmt3aD/D CLL (60% overlap), and the effects on gene expres-
sion were broader, as 10% of hypomethylated promoters were
associated with overexpression. These data demonstrate that
loss of Dnmt3a in CLL results in genome-wide deregulation of
DNA methylation, and this is primarily due to hypomethylation.
Based on three simple points—Dnmt3a is a DNA methyltrans-
ferase, promoter methylation is associated with gene repression,
Figure 7. HOC Genes Are Putative Drivers
of Dnmt3a-Deficient CLL
(A) The number of genes differentially expressed
and differentially methylated at the promoter re-
gion in Dnmt3aD/D CLL and Dnmt3a+/ CLL. The
number of genes with corresponding methylation
and expression changes are shown in the gray
boxes.
(B) Promoter methylation for HOC genes in B-1a,
Dnmt3a+/D CLL, and Dnmt3aD/D CLL is shown
within boxes. Similarly, fold differences in gene
expression between Dnmt3a+/D CLL relative to
B-1a and Dnmt3aD/D CLL relative to B-1a is
shown. Asterisk denotes genes overexpressed in
human CLL.
(C) COBRA assay of 26 HOC gene promoters in
Dnmt3a+/D CLL (+/D), Dnmt3a+/ CLL (+/) and
Dnmt3aD/D CLL (D/D) samples. Undigested (U)
and digested (D) fragments correspond to un-
methylated and methylated DNA, respectively.
CpG and M indicates a fully methylated control
and undigested PCR fragments, respectively.
Asterisk denotes unconfirmed target.and loss of one Dnmt3a allele is sufficient to induce CLL—we
speculated that genes hypomethylated and overexpressed in
bothmouseDnmt3a+/ andDnmt3aD/DCLL likely represent onco-
genic drivers. Using statistical approaches, we identified a signa-
tureof 26genescommonly hypomethylatedandoverexpressed in
both mouse Dnmt3a+/ and Dnmt3aD/D CLL (HOC genes).
The hypomethylation of HOC gene promoters in Dnmt3a+/
and Dnmt3aD/D CLL could be linked to Dnmt3a inactivation in
normal cells, due to lack of Dnmt3a’s de novo or maintenance
activity during normal development of B-1a cells. However, we
found that HOC gene promoters are hypermethylated in both
normal Dnmt3a+/+ and Dnmt3a+/ B-1a cells, suggesting that
loss of one allele of Dnmt3a does not affect the methylation
status of promoters in normal B-1a cells. Lack of promoter
methylation could also result from increased proliferation of tu-Cell Rmor cells without a direct link to Dnmt3a.
However, analysis of promoter methyl-
ation of several HOC genes revealed
that, while these promoters are hypome-
thylated in Dnmt3a+/ and Dnmt3aD/D
CLL, they remain hypermethylated in
IRF4/;Vh11 CLL. Such results suggest
that the lack of Dnmt3a maintenance
methylation activity, rather than prolifer-
ation of tumor cells, is responsible for
the promoter hypomethylation in HOC
genes. It is, however, still important to
point out that we do not have definitive
evidence that observed hypomethy-
lated changes are strictly dependent on
Dnmt3a. Further studies will need to
address whether promoter hypomethy-
lation is a function of Dnmt3a-deffi-
ciency, proliferation, aging, or a combi-
nation of these.Interestingly, IPA using expression data for the HOC signature
placed 24 genes into the category of ‘‘Cancer.’’ A closer exam-
ination of this signature revealed a number of genes with the po-
tential to transform cells, including those of hematopoietic origin.
For example, Zbtb32 belongs to a list of genes whose increased
expression was recently identified to have positive predictive
value in determining whether patients will develop CLL later in
life (Chadeau-Hyam et al., 2014). Gas7, a growth-arrest-specific
gene is overexpressed in hairy cell leukemia, a slow growing
malignancy thought to, like CLL, arise frommemory B cells (Dun-
phy, 2006). The PVT1 gene locus encodes a long non-coding
RNA and several microRNAs with predicted oncogenic func-
tions, as it is a target of tumorigenic translocations and retroviral
insertions, and its overexpression correlates with upregulation of
MYC. Specifically, PVT1 encodes miR-1206 and miR-1204. Theeports 15, 1190–1201, May 10, 2016 1199
former, miR-1206, is upregulated in tumors of B cell origin such
as Burkitt’s lymphomas in humans and plasmacytomas in mice
(Beck-Engeser et al., 2008; Guan et al., 2007; Huppi et al.,
2008). In mice, miR-1204 is overexpressed in retrovirally induced
T cell lymphomas (Beck-Engeser et al., 2008). PDCD1LG2 (PD-
L2) is aberrantly upregulated in a significant number of patients
with AML (Yang et al., 2014). We also found that several HOC
genes were reported to be overexpressed in the Em-TCl1mouse
model as well as other mouse models of CLL. Slc7a7, Pstpip2,
Pon3, Il5ra, and the uncharacterized gene 1810046K07Rik
(C11orf53) are among the top 25 overexpressed genes in the
Em-TCL1 mouse model of CLL (Nganga et al., 2013). Slc7a7,
Arid3b, and Ppil1 are overexpressed in CLL/B cell malignancies
that develop in Em-miR-1792 transgenic mice overexpressing
miR-1792 polycistronic microRNA (Sandhu et al., 2013).
Some of these genes or their close relatives show putative onco-
genic functions. For example, human PON3 is markedly overex-
pressed in a variety of human neoplasias and has antiapoptotic
function (Schweikert et al., 2012). The role of another HOC gene,
SLC7A7, is poorly understood, but its relative SLC7A5 (LAT1) is
associated with high proliferation and poor prognosis in newly
diagnosed patients with multiple myeloma—a B cell malignancy
(Isoda et al., 2014). Altogether, these data strongly suggest that
the HOC signature contains oncogenic drivers of CLL that
contribute to the transformation of B-1a cells. However, the
genes that are oncogenic drivers of CLL do not necessarily
need to be limited to only hypomethylated and overexpressed
genes. Indeed, other cancer-associated genes are found in
gene expression profiles obtained from Dnmt3a+/ and
Dnmt3aD/D CLL. Whatever the case, at a minimum, the HOC
signature represents genes likely regulated by Dnmt3a-depen-
dent methylation, providing an opportunity to study the nature
of deregulated methylation during disease development and
progression. Future functional studies will dissect the potential
contribution of these genes to the development of CLL.
EXPERIMENTAL PROCEDURES
Mouse Studies
All mice used in these studies were of the FVB/N background and were
generated using standard genetic crosses. To obtain mice with a germline
transmission of the Dnmt3a allele, we crossed EmSRa-tTA;Teto-Cre;
Dnmt3afl/fl mice with FVB mice, taking advantage of our observation that
the EmSRa-tTA transgene is expressed in germ cells (data not shown). To
generate Dnmt3a+/, we subsequently bred out transgenes by crossing
obtained mice with FVB mice. Mice were harvested at the experimental
endpoint of 16 months.
FACS Analysis
Mice diagnosed with MBL had between 2% and 20%B-1a in the blood at time
of harvest, while those diagnosed with CLL had > 20%B-1a in the blood. Mice
diagnosed with MPD had profound expansion of CD11b+Gr-1+ cells in the
blood (>70%) and spleen (>40%).
WGBS
Splenic B-1a cells (EGFP+CD5+CD19+B220+) were FACS sorted from
Dnmt3a+/D (EmSRa-tTA;Teto-Cre;Dnmt3+/fl;Rosa26LOXPEGFP/EGFP; n = 1) and
Dnmt3aD/D (EmSRa-tTA;Teto-Cre;Dnmt3fl/fl;Rosa26LOXPEGFP/EGFP; n = 1)
mice suffering from CLL. Control B-1a cells were isolated from healthy
age-matched Dnmt3a+/+ control mice (EmSRa-tTA;Teto-Cre;Dnmt3a+/+;
Rosa26LOXPEGFP/EGFP; n = 1). Details regarding the number of aligned1200 Cell Reports 15, 1190–1201, May 10, 2016sequencing reads per sample can be found in Table S9. An additional descrip-
tion of the data analysis is provided in the Supplemental Experimental
Procedures.
Statistical Analysis
In Figures 1C, 1H, 2F, 2G, 5B, and 5D, the p values were calculated using
two-sample Student’s t tests in Excel. For Figure 3D, a Bonferroni’s multiple
comparison test was used to assess statistical difference between groups.
For RNA-seq data, CuffDiff software was used for the statistical analysis of
differentially expressed genes (q value < 0.05). DMRs were determined using
the R software package DSS (Wu et al., 2015). A Wald test was performed at
each CpG site to obtain p values. For MSCC, count data were analyzed by
edgeR, which uses Bayesian estimation and exact tests based on the negative
binomial distribution to make pairwise comparisons. The p values were esti-
mated using the Benjamini Hochberg method. Only a p < 0.05 was considered
significant.
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